The Pharmaceutical Journal
Vol 270 No 7244 p507
12 April 2003

This article
Reprint
Photocopy

News summary

Related websites
The New England Journal of Medicine abstract (more)

Benefit of new antiviral continue

The benefits of adding enfuvirtide (T-20, Fuzeon), an HIV type-1 fusion inhibitor, to an optimised antiretroviral regimens in patients who had previously received multiple antiretroviral drugs has been reported online in The New England Journal of Medicine.

Enfuvirtide, which is being developed by Roche and Trimeris, is expected to be launched in the United Kingdom in the next few months.